Source: StemCells, Inc.
Posted: October 7, 2010 9:00 a.m. EDT
Summary:
PALO ALTO, Calif., – StemCells, Inc. today provided an update on its ongoing Phase I clinical trial in Pelizaeus-Merzbacher Disease ( PMD), a fatal myelination disorder that afflicts male children. Two of four planned patients for this trial have now been enrolled and transplanted with the Company’s HuCNS-SC ® human neural stem cells. The Company anticipates enrolling a third patient before year-end and the fourth shortly thereafter. This clinical trial is the first to evaluate purified neural stem cells as a potential treatment for a myelination disorder. The trial is being conducted at UCSF Benioff Children’s Hospital.
